Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome
It has been shown in previous studies that botulinum toxin type A (BTX-A) can effectively relieve the motor symptoms of Meige syndrome. However, its effect on non-motor symptoms (NMS) and quality of life (QoL) has not been comprehensively studied. This study aimed to explore the effects of BTX-A on...
Saved in:
Published in | Frontiers in neurology Vol. 14; p. 1115482 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
09.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | It has been shown in previous studies that botulinum toxin type A (BTX-A) can effectively relieve the motor symptoms of Meige syndrome. However, its effect on non-motor symptoms (NMS) and quality of life (QoL) has not been comprehensively studied. This study aimed to explore the effects of BTX-A on NMS and QoL and to clarify the relationship between changes in motor symptoms, NMS, and QoL after BTX-A.
Seventy-five patients were recruited for the study. All patients were assessed by a series of clinical assessments before, one, and 3 months after BTX-A treatment. Dystonic symptoms, psychiatric disturbances, sleep disorders, and QoL were evaluated.
After 1 and 3 months of BTX-A treatment, the scores of motor symptoms, anxiety, and depression were significantly decreased (
< 0.05). Except for general health, the scores of the other 36-item short-form health survey QoL subitems were significantly improved after BTX-A (
< 0.05). After 1 month of treatment, the changes in anxiety and depression were not correlated with changes in motor symptoms (
> 0.05). Still, they were negatively correlated with changes in physical functioning, role-physical and mental component summary QoL (
< 0.05).
BTX-A effectively improved motor symptoms, anxiety, depression, and QoL. Anxiety and depression improvement did not correlate with motor symptom changes after BTX-A, and QoL improvements were strongly associated with psychiatric disturbances. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Kazuya Yoshida, National Hospital Organization Kyoto Medical Center, Japan Reviewed by: Michael Hutchinson, St Vincent's University Hospital, Ireland; Matteo Costanzo, Sapienza University of Rome, Italy This article was submitted to Movement Disorders, a section of the journal Frontiers in Neurology |
ISSN: | 1664-2295 1664-2295 |
DOI: | 10.3389/fneur.2023.1115482 |